Landos Biopharma, a clinical-stage biopharmaceutical company, has completed a USD60m Series B financing round, it was reported yesterday.
The financing was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors, including Osage University Partners and PBM Capital.
The financing is intended to support Phase two global clinical trials for the company's lead product, BT-11, in ulcerative colitis and Crohn's disease.
Aptamer Group secures GBP112,000 contract with top 10 global pharmaceutical company
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
Jubilant HollisterStier's Washington facility launches new high-speed isolator based Line
Assembly Biosciences reports positive interim Phase 1b data for herpes treatment candidate ABI-5366
Dubai Culture and Zayed University Invite Global Creatives to Participate in ISEA2026
VolitionRx proposes underwritten public offering of common stock and common stock warrants
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
WuXi Biologics recognised with MSCI AAA ESG rating for third consecutive year
Tempus selected by ARPA-H to provide CRO and testing services for ADAPT cancer programme
Novo Nordisk to acquire Akero Therapeutics in USD5.2bn deal to strengthen MASH pipeline
Zelluna receives positive MHRA feedback and advances UK clinical plans for ZI-MA4-1